Filing Details
- Accession Number:
- 0001193125-24-040065
- Form Type:
- 13D Filing
- Publication Date:
- 2024-02-19 19:00:00
- Filed By:
- Tcg Crossover Gp I, Llc
- Company:
- Kalvista Pharmaceuticals Inc. (NASDAQ:KALV)
- Filing Date:
- 2024-02-20
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| TCG Crossover GP I | 0 | 2,700,840 | 0 | 2,700,840 | 2,700,840 | 6.52% |
| TCG Crossover Fund I | 0 | 2,700,840 | 0 | 2,700,840 | 2,700,840 | 6.52% |
| Chen Yu | 0 | 2,700,840 | 0 | 2,700,840 | 2,700,840 | 6.52% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
KALVISTA PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
483497 10 3
(CUSIP Number)
Craig Skaling
Chief Financial Officer
TCG Crossover GP I, LLC
705 High St.
Palo Alto, CA 94301
(650)-924-9424
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
February 7, 2024
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
| CUSIP No. 483497 10 3 | 13D | |||
| 1. | Name of Reporting Persons
TCG Crossover GP I, LLC | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,700,840 (1) | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,700,840 (1) | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,700,840 (1) | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.52% (2) | |||||
| 14. | Type of Reporting Person (See Instructions)
OO | |||||
| (1) | These securities are held by TCG Crossover I (as defined in Item 2(a) below) and consist of (i) 2,518,370 shares of Common Stock (as defined in Item 1(a) below) and (ii) 182,470 shares of Common Stock underlying pre-funded warrants which are exercisable within 60 days of the date hereof. TCG Crossover GP I (as defined in Item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. |
| (2) | Based on 41,437,770 shares of the Issuers Common Stock outstanding (assuming the underwriters do not exercise the option to purchase additional shares), as disclosed by the Issuer in its prospectus supplement dated February 14, 2024 and filed with the Securities and Exchange Commission (the Commission) pursuant to Rule 424(b)(5) on February 16, 2024 (the Prospectus Supplement). |
| CUSIP No. 483497 10 3 | 13D | |||
| 1. | Name of Reporting Persons
TCG Crossover Fund I, L.P. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
WC | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
Delaware | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,700,840 (1) | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,700,840 (1) | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,700,840 (1) | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.52% (2) | |||||
| 14. | Type of Reporting Person (See Instructions)
PN | |||||
| (1) | These securities are held by TCG Crossover I and consist of (i) 2,518,370 shares of Common Stock and (ii) 182,470 shares of Common Stock underlying pre-funded warrants which are exercisable within 60 days of the date hereof. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. |
| (2) | Based on 41,437,770 shares of the Issuers Common Stock outstanding (assuming the underwriters do not exercise the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement. |
| CUSIP No. 483497 10 3 | 13D | |||
| 1. | Name of Reporting Persons
Chen Yu | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
AF | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
United States of America | |||||
| Number of Shares Beneficially Owned by Each Reporting Person With
| 7. | Sole Voting Power
0 | ||||
| 8. | Shared Voting Power
2,700,840 (1) | |||||
| 9. | Sole Dispositive Power
0 | |||||
| 10. | Shared Dispositive Power
2,700,840 (1) | |||||
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,700,840 (1) | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
6.52% (2) | |||||
| 14. | Type of Reporting Person (See Instructions)
IN | |||||
| (1) | These securities are held by TCG Crossover I and consist of (i) 2,518,370 shares of Common Stock and (ii) 182,470 shares of Common Stock underlying pre-funded warrants which are exercisable within 60 days of the date hereof. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. |
| (2) | Based on 41,437,770 shares of the Issuers Common Stock outstanding (assuming the underwriters do not exercise the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement. |
| CUSIP No. 483497 10 3 | 13D | |||
Item 1. Security and Issuer
This joint statement on Schedule 13D/A (this Statement) is filed with respect to the common stock, par value $0.001 per share (Common Stock), of KalVista Pharmaceuticals, Inc., a Delaware corporation (the Issuer). The address of the principal executive offices of the Issuer is 55 Cambridge Parkway, Suite 901 East, Cambridge, MA 02142. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
Item 2. Identity and Background.
(a) This Amendment No. 1 (Amendment No. 1) amends and supplements the Schedule 13D originally filed with the Commission on January 9, 2023 (the Original Schedule 13D). This Statement is being filed by TCG Crossover Fund I, L.P. (TCG Crossover I), TCG Crossover GP I, LLC (TCG Crossover GP I and together with TCG Crossover I, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to Original Schedule 13D as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Persons pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.
Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D. This Statement is being filed to reflect the sales of shares of Common Stock of the Issuer by the Reporting Persons that occurred between January 25, 2024 and February 16, 2024, as well as to reflect an increase in the number of shares of Common Stock outstanding, caused by, among other things, the Issuers sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D.
Item 5. Interest in Securities of the Issuer
Item 3(c) of the Original Schedule 13D is hereby amended to add the following language:
(c) Except as otherwise reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuers securities within the past 60 days.
TCG Crossover I made the following open market sales of Common Stock between January 25, 2024 and February 16, 2024.
| Date of Sale | Shares Sold | Price Per Share | Aggregate Sales Price | |||||||||
| January 25, 2024 | 23,142 | $ | 12.8508 | (1) | $ | 297,393.00 | ||||||
| January 26, 2024 | 62,500 | $ | 13.1312 | (1) | $ | 820,702.84 | ||||||
| January 29, 2024 | 22,098 | $ | 13.8243 | (2) | $ | 305,489.44 | ||||||
| January 29, 2024 | 47,902 | $ | 14.3388 | (3) | $ | 686,857.17 | ||||||
| January 30, 2024 | 139,811 | $ | 14.4772 | (1) | $ | 2,021,989.60 | ||||||
| February 7, 2024 | 79,629 | $ | 14.6622 | (1) | $ | 1,168,728.89 | ||||||
| February 8, 2024 | 125,921 | $ | 14.7163 | (1) | $ | 1,853,087.96 | ||||||
| February 9, 2024 | 39,439 | $ | 16.0301 | (1) | $ | 632,210.41 | ||||||
| February 12, 2024 | 87,015 | $ | 16.0981 | (1) | $ | 1,400,776.79 | ||||||
| February 13, 2024 | 77,520 | $ | 15.9253 | (1) | $ | 1,231,485.62 | ||||||
| February 15, 2024 | 123,609 | $ | 16.2225 | (1) | $ | 2,005,247.00 | ||||||
| February 16, 2024 | 48,539 | $ | 14.9122 | (1) | $ | 723,823.28 | ||||||
| (1) | Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| (2) | Price is the volume weighted average selling price of all sales by the Reporting Persons. These shares were sold in multiple transactions at prices ranging from $13.15 to $14.14, inclusive. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| (3) | Price is the volume weighted average selling price of all sales by the Reporting Persons. These shares were sold in multiple transactions at prices ranging from $14.15 to $14.50, inclusive. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| February 20, 2024 | ||
| TCG Crossover Fund I, L.P. | ||
| By: | TCG Crossover GP I, LLC | |
| Its: | General Partner | |
| By: | /s/ Craig Skaling | |
| Authorized Signatory | ||
| TCG Crossover GP I, LLC | ||
| By: | /s/ Craig Skaling | |
| Authorized Signatory | ||
| Chen Yu | ||
| /s/ Craig Skaling, as attorney-in-fact for Chen Yu | ||